Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.51 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.49 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.49 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440643 | 1.00 | MAOB (0.60) | MAOBMAPTNPC1LMNAF3 | |
| SCHEMBL3440695 | 0.86 | MAOB (0.60) | MAOBMAPTNPC1LMNAF3 | |
| SCHEMBL3440696 | 0.86 | MAOB (0.60) | MAOBMAPTNPC1LMNAF3 | |
| SCHEMBL3440509 | 0.85 | MAOB (0.64) | MAOBMAPTNPC1LMNAF3 | |
| SCHEMBL3440508 | 0.85 | MAOB (0.64) | MAOBMAPTNPC1LMNAF3 | |
| SCHEMBL3440702 | 0.84 | ABCB1 (0.51) | MAOBMAPTNPC1LMNAABCG2 | |
| SCHEMBL3440703 | 0.84 | ABCB1 (0.51) | MAOBMAPTNPC1LMNAABCG2 | |
| SCHEMBL30383779 | 0.84 | ABCB1 (0.51) | MAOBMAPTNPC1LMNAABCG2 | |
| SCHEMBL25208761 | 0.84 | MAOB (0.72) | MAOBMAPTNPC1LMNAF3 | |
| SCHEMBL25193709 | 0.84 | MAOB (0.72) | MAOBMAPTNPC1LMNAF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | claimed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | disclosed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAOB 1004/4885MAPT 3297/4885NPC1 1378/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885MAPT 3512/4885NPC1 1908/4885 |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | LIPC, CYP46A1, HMGCR | MAOB 2303/4885MAPT 4801/4885NPC1 110/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885MAPT 3512/4885NPC1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.